Loading
The body that inspects and accredits stem cell transplant, cord blood and cellular therapy programmes against shared quality standards, in the US and abroad.
The Foundation for the Accreditation of Cellular Therapy was formed in 1995 by experts in the emerging field of cellular therapy to set consensus standards for medical and laboratory practice, according to its own story page. Its voluntary accreditation programme inspects programmes against those standards; it co-publishes standards with JACIE, the accreditation committee of ISCT and EBMT, and performs inspections around the world. The IRS record lists it in Omaha, Nebraska. The IRS Business Master File lists revenue of about $7 million for the tax year ending December 2025.
Shares Autologous stem cell transplant (high-dose therapy), Allogeneic stem cell transplantation, CAR-T cell therapy.
Shares Allogeneic stem cell transplantation, CAR-T cell therapy.
Shares Autologous stem cell transplant (high-dose therapy), Allogeneic stem cell transplantation.
Shares Allogeneic stem cell transplantation, CAR-T cell therapy.
Shares Autologous stem cell transplant (high-dose therapy), Allogeneic stem cell transplantation.
Shares Autologous stem cell transplant (high-dose therapy), CAR-T cell therapy.
Shares Allogeneic stem cell transplantation, CAR-T cell therapy.
Shares Autologous stem cell transplant (high-dose therapy), Allogeneic stem cell transplantation.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/